ReCAP

AAD 2025 HS Highlights From the AAD 2025 Annual Meeting Hidradenitis suppurativa (HS) highlights from AAD 2025 include studies of HS patients' risk for cardiovascular disease or emergency department visits, and takeaways on optimizing use of HS therapies.
ReCAP, March 31, 2025
AAD 2025 Urticaria Highlights From AAD 2025 Urticaria highlights from AAD 2025 include late-breaking results from a phase 1b/2a study of the anti-c-Kit antibody placulumab, and positive results from the phase 3 studies of remibrutinib.
ReCAP, March 31, 2025
AAD 2025 Atopic Dermatitis Highlights From AAD 2025 Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.
ReCAP, March 31, 2025
AAAAI 2025 Urticaria, Angioedema, and Anaphylaxis Highlights From AAAAI The changing therapeutic landscape for urticaria, angioedema, and anaphylaxis is evidenced by emerging treatments reported at AAAAI and discussed by Dr Ruchi Gupta.
ReCAP, March 24, 2025
ACTRIMS 2025 Disease-Modifying Therapies for RRMS From ACTRIMS 2025 Updates on therapies for relapsing-remitting MS from ACTRIMS 2025 include the effects of B-cell-depleting agents in minority populations and a novel approach utilizing CAR T-cells to target CD19.
ReCAP, March 20, 2025
Ovarian Cancer Highlights From ESGO 2025 Ovarian cancer highlights from ESGO 2025 include a prospective study on neoadjuvant chemotherapy, new data on PARP inhibitors, and KEYLYNK-001 trial results on adding pembrolizumab to chemotherapy.
ReCAP, March 14, 2025
Renal Cell Carcinoma Highlights From ASCO GU 2025 Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.
ReCAP, March 06, 2025
Key Updates in Early Breast Cancer From SABCS 2024 Key updates from SABCS 2024 in early breast cancer include the COMET study on DCIS recurrence, INSEMA trial on SLNB omission, and OlympiA updates on adjuvant olaparib, shared by Dr Harold Burstein.
January 09, 2025
Updates in ER-Positive Breast Cancer From SABCS 2024 Updates in ER+ breast cancer from SABCS 2024 include the EMBER-3 trial of novel oral SERD imlunestrant, PATINA trial results, and updated analysis from TAILORx, as reported by Dr Harold Burstein.
January 02, 2025
Key Studies in Acute Lymphoblastic Leukemia From ASH 2024 Highlights in acute lymphoblastic leukemia (ALL) from ASH 2024 include significant results for blinatumomab in pediatric ALL, potential use of asciminib, and frontline use of CAR-T cell therapy.
January 02, 2025
Key Studies in Chronic Lymphocytic Leukemia From ASH 2024 Practice-changing studies in both frontline CLL and relapsed/refractory disease, presented at ASH 2024, are discussed by Dr Jennifer Woyach.
December 30, 2024
Paroxysmal Nocturnal Hemoglobinuria Takeaways From ASH 2024 Symptom improvement with novel therapies and better patient-reported outcomes, as well as breakthrough hemolysis control, are among the paroxysmal nocturnal hemoglobinuria highlights from ASH 2024.
December 30, 2024
Novel Insights in Thrombotic Disorders From ASH 2024 Rilzabrutinib and eltrombopag in immune thrombocytopenia, and the place of oral direct anticoagulation in venous thromboembolism, are among the novel insights in thrombotic disorders from ASH 2024.
December 30, 2024
DLBCL Highlights From ASH 2024 Dr John Leonard shares key updates on DLBCL at ASH 2024, including long-term POLARIX trial data, ctDNA insights, and real-world results for polatuzumab, liso-cel, and bispecifics after CAR-T failure.
December 30, 2024
Chronic Myeloid Leukemia Highlights From ASH 2024 Highlights in chronic myeloid leukemia from ASH 2024 include data on efficacy of asciminib over TKIs, benefit from the third-generation TKI olverembatinib, and importance of molecular monitoring.
December 30, 2024
New Directions in Anemia and Related Disorders From ASH 2024 Strategies to reduce disease burden in alpha- or beta-thalassemia, sickle cell disease, and polycythemia vera, and insights into anemia in IBD, are among anemia highlights from ASH 2024.
December 23, 2024
Psoriatic Arthritis Highlights From ACR Convergence 2024 Highlights in psoriatic arthritis from ACR 2024 include results of methotrexate added to DMARD therapy, responses to bimekizumab, and improvements gained by upadacitinib after prior TNF inhibitor use.
December 11, 2024
Highlights in Food Allergy Studies From ACAAI 2024 Key food allergy studies from ACAAI 2024 include data on the pharmacokinetics of different epinephrine delivery methods, early allergen exposure, and food allergy anxiety in children and caregivers.
November 18, 2024
Glomerular Disease Highlights From ASN Kidney Week 2024 Glomerular disease highlights from ASN 2024 include data on atacicept benefits in IgA nephropathy, protein reduction from pegcetacoplan, and a possible new therapy for membranous nephropathy.
November 13, 2024
ASRS 2024 Dry AMD Highlights From ASRS 2024 Key data on dry age-related macular degeneration and geographic atrophy from ASRS 2024 include real-world experience of recently approved therapies and emerging agents with new mechanisms of action.
ReCAP, November 12, 2024

All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.